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Transforming growth factor-/I (TGF-/1) and a glucocorticosteroid, Dexamethasone (DXM), both cause transcriptional induction of Epstein-Barr 
virus (EBV) early antigens (EA) in Daudi lymphoma cells. The viral induction occurs through the viral promoter DR overlapping an origin of 
replication which is active during the lytic cycle. Each hormone requires specific regions on the DR promoter. Since these regions also mediate 
the action of two viral transcription factors, EBI and R, it may be emphasized that EBI and/or R are involved in the EA induction process by 
TGF-/I and by DXM. 
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1. INTRODUCTION 
The transforming growth factor-p (TGF-fl) belongs 
to a subgroup of a large family of peptidic hormones [ 1 J 
and is known to display a variety of regulatory func- 
tions in normal and in neoplastic cells. TGF-0 affects 
cell proliferation and differentiation by exerting either 
a stimulatory or an inhibitory effect. Of special impor- 
tance is the suppressive action of TGF-P on the growth 
of T and B lymphocytes, suggesting practical applica- 
tions as an anti-inflammatory or an immunosuppressive 
agent [2]. It has recently become clear that, in addition 
to its role in growth control, TGF-P stimulates the syn- 
thesis of several extracellular matrix proteins, including 
type 1 collagen and fibronectin [3], and inhibits the ex- 
pression of several proteases [4]. The latter activities 
confer to TGF-P a major physiological role in wound 
healing [S]. 
It is well established that the action of TGF-P is 
mediated by an interaction between the growth factor 
and a specific receptor located in the plasma mem- 
brane. It is clear that TGF-fl acts on gene expression 
primarily at the transcriptional level [6-91. 
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Much information is available on the regulation of 
transcription of cellular and viral genes mediated by 
glucocorticoid hormones (for a review see [lo]). In Et 
cells latently infected with the Epstein-Barr virus 
(EBV), a double-stranded DNA Herpes virus, TGF-fl, 
and the potent synthetic glucocorticoid, Dex- 
amethasone (DXM), are both able to induce the syn- 
thesis of viral early antigens (EA) [l 11. Therefore, we 
decided to compare the effects of TGF-P and DXM at 
the transcriptional level. Using the CAT system 
developed by Gorman et al. [ 121 we analysed the target 
sequences involved in the induction of the EBV early 
promoters. 
2. MATERIALS AND ME’rHODS 
2. I. Steroids 
DXM (9a-fluoro-16cu-methyl-l IS, 17@,21-trihydroxy-l,rl-pregna- 
diene-3,20-dione) and RU486 (17,&hydroxy-I l&(4-dimethylamino- 
phenyl)-l7o-(l-propynyl)-estra-4,9-diene-3-one) were kind gifts from 
Roussel UCLAF. TGF-fl was either prepared by D.A. Lawrence [13] 
or purchased from R&D (Minneapolis, USA). 
2.2. Cell litws ntwf steroid Ireutt?m~s 
EBV-positive Daudi cells were grown in RPM1 1640 supplemented 
with 10% charcoal-treated foetal calf serum and 2 mM glutamiue in 
a Solo CO2 atmosphcrc at 37°C. For induction, TGFB (5 ng/ml) and 
steroids (3 /[M) were added to lymphoid cells during 48 h. 
Plasmidic construction pKCAT was obtained try inscrtittg the EBV 
promoter DR in front of the buctcrial CAT gcnccoding scque~~cc [ 141. 
Dclction constructs wcrc obtaiucd as dcscribcd previously (I 51. 
Plnstnid pNCA7’, which contains 2 kb of the promoter controlling the 
csprcssion of tltc EBV trnnscription faclor EBI in front of the CAT 
rcporlcr gcnc, was a gift from Uri~r G. (uiipublislicd results). 
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2.4. Trmsfection experiments 
One day before transfection, Daudi cells were suspended at a 5 x 
10’ cell density per ml in fresh medium. Lymphoma cells were 
transfected with 2 pg of CAT reporter gene by the DEAE-dextran 
method [lG]. Before induction, the transfected cells were pooled and 
sampled in order to get the same transfection efficiency in each assay. 
2.5. CA 7 rmsays 
These tests were essentially performed as described earlier 1121. The 
sonication was replaced by lysing, the cells during 5 cycles of freezing- 
thawing. After centrifugation, the supernatant was assayed for CAT 
activity. The reaction time and quantity of extract were selected to 
stay in the linear range of the reaction. Protein concentration was 
determined with the BioRad assay kit. 
A 
3. RESULTS 
3.1. TGF-,8 and DXM activate the DR promoter- 
Daudi lymphoma cells were transfected with the 
recombinant plasmid pKCAT, which contains, inserted 
5’ to the bacterial CAT encoding gene, the EBV early 
promoter DR. This promoter controls the EA synthesis 
and overlaps an origin of replication active only during 
the lytic cycle 1171 (Fig. 1). Transfected cells were 
grown either with or without TGF-B (5 ng/ml) or DXM 
(3 PM) for 48 h, and CAT expression was measured. 
EBl R 
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I$. I I (A) Linear representation of the EUV genome and of the pkamids pKCAT and pNCAT. pKCAT contains the CAT coding sequence under 
[he control of ~hc EBV DR promoter. The lacalisations of the scqucnccs responsive IO the viral transcription factors ED1 and R arc indicated 
respectively as ZRE and RRE clenicnts. pNCAT contains the promoter of EBI in front of the CAT coding sequence; the locallsations of the API 
scqucncc and of the EUI responsive sequences, ZHlXI and ZRE-Zt urc indicated, (8) Delctiou mutants of the DR promoter In pKCAT construct. 
The blnck box represents the distnl enhancer elemctlt rontainlng the R responxivcclcmcut, E, and the hatched boxes rcprc;cnt the EBI binding sites. 
Restriction rites rbbrevlatlonn: H = Iflrrdlll; N = Mel; Bci m &/I; BG2 = &III. 
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The addition of TGF-fl to Daudi cells caused a 
marked increase in the level of CAT activity (Fig. 2). 
Maximal stimulation of CAT activity was measured 
with a 5 ng/ml concentration of TGF-,& (data not 
shown). This value is close to the amount required for 
TGF-fl to express other effects like autoactivation of its 
own promoter or activation of the collagen promoter 
[la]. By comparing the induction due to TGF-,L? or to 
DXM, a higher level of CAT induction was observed 
with the growth factor. Routinely, a 17-fold induction 
and a g-fold one were measured respectively with TGF- 
,L?? (lane 1) and the glucocorticoid (lane 2). When the two 
compounds were given simultaneously, an additive in- 
duction ratio of about 23-fold was observed (lane 4). 
The CAT induction observed with TGF-,O or DXM 
represents a true activation of the DR promoter. It is 
not a consequence of cell proliferation, since no change 
in the growth rate occurred in the presence of the drugs. 
The induction of CAT expression suggests that both 
TGF-P and DXM act directly or indirectly on the DR 
promoter. Moreover, the two compounds did not in- 
terfere with one another since simultaneous administra- 
tion leads to an additive effect, This observation also 
suggests that the two inducers do not act through the 
same target(s) on the DR promoter. 
3.2. Effects of TGF-fi and DXM on mutants of the DR 
promoter 
In order to determine which sequences are involved in 
the induction of the DR promoter by TGF-fl and 
1 2 3 4 
Pig, 2. Effect of DXM and TGF-8on the DR promoter in Daudi cells. 
CAT assays were performed essentially as dcscribcd in section 2. 
Extract from cells transfccted with pKCAT (lane I) in prescncc of 
TGFd (5 ng/ml); (fanc 2) in the prcsencc of DXM C3 FM); (lane 3) in 
the absence of indxers; (tan& 4) In the prcscncc of TQF-& (5 ng/mf) 
and UXM (3,tM). The data prcsetltcd corresl~ol~d to a typical 
glucocorticoids, we tested several deletion mutants 
(Fig. 1B). Deletion of the region between -897 and 
-639 (mutant A7) reduced TGF-&? induction to the 
basal level (Fig. 3A). In order to identify other 
regulatory elements in this promoter, region -897 to 
-639 was positioned at an approximate constant 
distance from the CAP site as it occurs in the wild-type 
promoter (mutants A7E to AlE, Fig. 1B). CAT ex- 
pression was not decreased by more than 50070 of the 
maximal induced level (referring to the pKCAT con- 
struct), providing the deletion was over position - 112. 
Deletions under position -112 unti1 -69 bp led to a 
drastic decrease to the basal level. These data suggest 
that the sequences mediating the response to TGF-fi are 
located in two distinct regions: one is located between 
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Fig. 3, Effect of DNA deletions in the DR promoter on CAT 
cxprcssion induced by TGF$ or DXM. Daudi cells were transfcctcd 
with pKCAT dclction mutants and treated with TGF$ (5 ng/ml) (A) 
or DXM (3cM) (8) during 48 h. Percent of CAT induction is 
detcrmincd by comparison with the CAT induction obtained with the 
original pkCAf construct ir! the presence of TGF-Bar DXM. Control 
cultures tronsfwcd with pKCAT were untreated. CAT activities arc 
the mcnn of two duplicotc indcpcndcnt experiments. 1000/o represents 
0.5 pmoi of clilorrlmphcnicol occtyiatcd per min and per mg of 
protein for TGF-,8 induction nncl 0.25 ,~mol of ~~~ior~m~t~enicol 
acetyhtcd per nrin md per rng of protein for DXM i~~ductjon, 
~rtdo~etlo~l~ steroids have been discarded from the fnedium, Uarr 3 
SD. 
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nucleotide -897 and -639 and the other one between 
nucleotide -112 and -69. 
The same series of mutants were used to analyse the 
transient expression under DXM treatment (Fig. 3B). 
We observed that the -897 to -639 region was not a 
prerequisite for DXM inducibility. Moreover, the 
stimulatory effect of DXM was higher with the mutants 
than with the wild-type construct. Indeed, the CAT ac- 
tivity obtained after deletion of the region spanning 
nucleotides -642 to -481 was 3-fold above the induc- 
tion rate measured with pKCAT. This observation sug 
gests an inhibitory role of this region in the induction 
process by DXM. However, when the deletion was ex- 
tended beyond position -112, CAT expression 
drastically decreased, as observed with TGF-fl. These 
experiments uggest hat only one region located bet- 
ween -112 and -69 is required to mediate DXM activa- 
tion of the DR promoter. 
From these results, we may conclude that the se- 
quence between -112 and -69, proximal to the TATA 
box, contains an important regulatory sequence which 
plays a role for the responsiveness of the DR promoter 
to TGF-P and to glucocorticoids. In addition, TGF-P 
requires the presence of a distal sequence, spanning 
nucleotide -897 to -639, to express its inducibiIity 
through the DR promoter. 
3.3. Effect of TGF-fl on the EBI promoter 
Recently it has been reported that four binding sites 
for the viral transcription factor EBl were located in the 
region spanning bp -69 to -112 [I 91, whereas an R- 
responsive enhancer is found between bp -639 and 
-847 [20,21]. Since EBI activates its own promoter 
[22,23] and the R promoter [24], we tested the effect of 
TGF-fl on the EBI promoter. Cells were transfected 
with plasmid pNCAT which contains about 2 kb of the 
EBl promoter region in front of the CAT gene 
(Fig. IA). Neither TGF-,~3 nor DXM significantly in- 
duced CAT expression through the EBl promoter in 
Daudi cells, suggesting that the two hormones do not 
up-regulate the expression of transactivator EBl (data 
not shown). Therefore, the effects of TGF-fl and DXM 
are likely to be mediated by DR promoter sequences, 
other than El31 and R responsive elements. Never- 
theless, in the case of TGF;O induction, a potentiation 
by EBl and R may occur. 
3.4. Antagonistic action of ~~4~6 on TGF-P or DXM 
induced CA T expression 
The synthetic steroid, RU486, which is acting as a po- 
tent antiglucocorticoid by inhibiting the synthesis of the 
viral EA induced by DXM, was also shown to slow 
down the EA induction brought over by TGF@ [I 11. 
Our previous work led us to investigate how the steroid 
antagonist interferes on the DR promoter-dependent i - 
duction of CAT expression, Therefore, Daudi cells 
were transfected with pKCAT and submitted to 48 h 
TGF-I3+RU486 
TOPO 
0- ; lb 15 2’0 
INDUCTION FOLD 
Fig. 4. Daudi cells were transfected with pKCAT and treated with 
TGF-@ (5 nglml) or DXM (3 PM) alone, or in combination with 
RU486 (3 PM). CAT activity was determined 48 h after transfection. 
fnduction-fold is determined in comparison with CAT activity 
obtained with untreated Daudi cells transfected with pKCAT. The 
results are the mean of 3 duplicate independent experiments. 
Endogenous steroids have been discarded from the medium. Bars = 
SD. 
treatments with the different combinations of DXM, 
TGF-fi and RU486 as shown in Fig. 4. RU486 did not 
modify the TGF-R-inducing octivvity on the DR pro- 
moter. These results do not correlate with the inhibitory 
effect exerted by RU486 on the EA expression 
measured in the cells by immuno~uorescence ill]. 
More work is required to understand this discrepancy 
which may depend on an interaction of RU486 at the 
post-transcriptional level, 
In contrast, RU486 exerts a strong antagonism of 
DXM induction at the transcriptional level; this result 
strengthens the fact that the CAT induction by DXM 
reflects a specific hormonal effect. 
4. DISCUSSION 
The transient expression experiments reported here 
demonstrate that the treatment of Daudi cells with 
TGF-P or DXM causes an activation of the vira1 DR 
promoter. This transcriptional activation could account 
to a large part for the increased EA synthesis observed 
earlier by immunofluorescence experiments [ 111. Dur- 
ing this study, we Iocalised specific regions in the DR 
promoter mediating the effect of TGF-P and of DXM, 
Two regions are involved in the activation by TGF@. 
The first one, located close to the TATA box (- 112 to 
-69 bp), is known to be also responsive to the EBV 
transactivato~ EBl 116,19], This viral transcription fac- 
tor is invoIved, with the EBV enhancer factor R, in the 
disruption of viral latency by activating the EBV earfy 
promoters. The second region spanning bp -897 to 
- 639 is an enhancer inducible by the EBV-early-factor 
R [24]. Thus two viral proteins, EBl and R, might be 
directly or indirectly involved in the EA induction pro- 
cess by TGF;O. Since TGF-~3 does not activate the ex- 
prcssion of EBi, an indirect process might be cm- 
phasired. 
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Recently, several authors have described the interac- 
tion of celIular proteins as second messengers for TGF- 
p induction. The activation of the collagen promoter by 
TGF-fi was shown to be mediated by a specific sequence 
corresponding to a binding site for nuclear factor 1 
(NFI) [6j. The autoactivation of the second promoter 
of the TGF-,81 gene was shown to be mediated by the 
AP-I (jun/fos) factor. Therefore there exist common 
targets for 12-U-tetrade~anoyl-~horbol 13-acetate 
(TPA) and TGF-fl on the DNA [7,8,25]. Conversely, 
gene inhibition by TGF-fl involves binding of a Fos- 
containing protein complex to a promoter sequence in 
the transin/stromelysin gene promoter termed the TGF- 
,@I inhibitory element [26]. A computer search on the 
DR promoter did not reveal any NFI-specific sequence 
in this promoter. In contrast, there is a TPA-responsive 
element in the EBl promoter which is known to be 
responsive to TPA [24,25]. However, no induction of 
the EBI promoter has been observed under TGF@ 
treatment. 
This present study suggests that the transcriptional 
reguIation of EBV genes by TGF-P is quite complex. 
MultipIe regulatory mechanisms inducing the synthesis 
or the activation of various factors, such as EBl and R, 
seem to be intimately involved in eliciting EA synthesis. 
Presently the responsiveness to TGIF-@ and DXM is not 
solved. This preliminary study prompted us to addi- 
tional experiments including DNA footprinting and gel 
shift assays in order to draw a clear relationship bet- 
ween the induction process and specific transcriptional 
factors which have to be identified. 
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